ATOSSA THERAPEUTICS I

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

05 Nov 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

04 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

31 Oct 2024 08:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

21 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

14 Oct 2024 17:08:43 By Nasdaq GlobeNewswire

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

01 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

10 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

28 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

21 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

20 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

12 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

22 Jul 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

02 Jul 2024 16:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

28 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

17 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa to Present at the Sidoti Small-Cap Investor Conference

05 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

28 May 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

15 May 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

13 May 2024 08:50:00 By Nasdaq GlobeNewswire